Emerging treatments

Aldosterone synthase inhibitors

Several of these agents are currently being assessed in phase II studies and hold some promise as alternative treatment approaches for PA.[137]​​ Further data are required to confirm their efficacy and safety in this situation. Remaining challenges include lack of specificity for aldosterone synthase (with evidence, for example, of reduced cortisol synthesising capacity) and inferior treatment effect when compared to mineralocorticoid receptor antagonism.[138][139]

Targeted therapy for specific mutations

Studies on the use of macrolides as treatment for individuals with mutations in the KCNJ5 gene are in progress.[140][141][142] For patients with CACNA1D or CACNA1H mutations, selective calcium-channel blockade may be possible.[49][57]​​​[134][143]​​

Use of this content is subject to our disclaimer